secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aldeyra Therapeutics, Inc. (ALDX)
CIK:        0001341235
Form:       8-K
Filed at:   2025-06-17T23:59:59+00:00
Accession:  0001213900-25-054949
Event type: regulatory
Sentiment:  neutral
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aldeyra resubmits reproxalap NDA for dry eye disease after CRL, Phase 3 trial met primary endpoint
--------------------------------------------------------------------------------

- Resubmitted NDA to FDA for topical ocular reproxalap to treat signs and symptoms of dry eye disease.
- Earlier CRL in April 2025 cited potential methodological issues; new Phase 3 dry eye chamber trial achieved primary endpoint (P=0.002).
- No notable baseline differences across treatment arms; mild transient instillation site discomfort was most common AE.
- PDUFA goal: FDA acceptance decision within 30 days, review completion within 6 months of submission.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1341235/000121390025054949/0001213900-25-054949-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1341235/000121390025054949/ea0245870-8k_aldeyra.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-054949

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer